Travere Therapeutics (TVTX) FCF Margin (2014 - 2026)

Travere Therapeutics has reported FCF Margin for 13 years, with the latest figure at 31.73% in Q1 2026.

• For the quarter ending Q1 2026, FCF Margin rose 1989.0% year-over-year to 31.73%; the trailing twelve-month figure through Mar 2026 stood at 56.32% (down 24.0% YoY), and the FY2025 full-year result was 406.28%, up 50493.0% from the prior year.
• FCF Margin for Q1 2026 stood at 31.73%, down from 17.25% in the prior quarter.
• The five-year high for FCF Margin was 35.44% in Q3 2025, with the low at 327.8% in Q3 2022.
• Historically, FCF Margin has averaged 141.55% across 5 years, with a median of 128.6% in 2022.
• Annual changes were most pronounced in 2022 — FCF Margin tumbled 38546 bps — and 2025, when it surged 23576 bps.
• Travere Therapeutics' FCF Margin stood at 261.54% in 2022, then surged by 45 bps to 142.92% in 2023, then jumped by 74 bps to 37.8% in 2024, then surged by 54 bps to 17.25% in 2025, then slumped by 84 bps to 31.73% in 2026.
• The last three FCF Margin figures came in at 31.73% (Q1 2026), 17.25% (Q4 2025), and 35.44% (Q3 2025), per Business Quant data.